Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Aberdeen | OTHER |
| Barts & The London NHS Trust | OTHER |
| Queen Mary University of London | OTHER |
Not provided
Not provided
Not provided
Not provided
To compare patient outcomes following interval and delayed cytoreductive surgeries and no surgery (neoadjuvant chemotherapy alone) and international variations in access to cytoreductive surgeries in women with advanced stage ovarian cancer.
Standard of care in patients with advanced ovarian cancer is primary cytoreductive surgery followed by chemotherapy. Neoadjuvant chemotherapy and interval cytoreductive surgery is an alternative in selected patients. Most data exist with interval cytoreductive surgery following 3-4 cycles of chemotherapy, however, some patients experience a delay. So far, the impact of delayed cytoreductive surgery (following >5 cycles of chemotherapy) on patient outcomes is poorly defined. There is also a paucity of data in women who undergo no surgery (>5 cycles of chemotherapy alone) and factors influencing international discrepancies in access to cytoreductive surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| interval cytoreductive surgery | women with stage III-IV ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) cytoreductive surgery |
| |
| delayed cytoreductive surgery | women with stage III-IV ovarian cancer, undergoing delayed (>5 cycles of chemotherapy) cytoreductive surgery |
| |
| no surgery | women with stage III-IV ovarian cancer, undergoing >5 cycles of chemotherapy alone (no cytoreductive surgery) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| interval cytoreductive surgery | Procedure | cytoreductive surgery after 3-4 cycles of chemotherapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| overall survival | defined from date of diagnosis to date of death by any cause or loss to follow-up | 15 years |
| progression free survival | defined from date of diagnosis to date of first recurrence | 15 years |
| facilitator/barriers to access to cytoreductive surgery | topic guide interview questionnaire to be used to elicit factors aiding/preventing access to cytoreductive surgery internationally | 15 years |
| Measure | Description | Time Frame |
|---|---|---|
| Post-operative morbidity | as per Clavien-Dindo classification | within 30 days from date of surgery |
| Resectability rates | R0 = no visible disease, R1 = <10mm visible residual disease, R2 = >10mm visible residual disease |
Not provided
Inclusion Criteria:
Women with stage III-IV ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) or delayed (>5 cycles of chemotherapy) cytoreductive surgeries or no cytoreductive surgery (>5 cycles of chemotherapy alone.
Exclusion Criteria:
Women undergoing recurrent cytoreductive surgery.
female
Not provided
women with stage III-IV ovarian cancer
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Faiza Gaba | Contact | +442035942053 | faiza.gaba1@abdn.ac.uk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Royal London Hospital | Recruiting | London | E1 1FR | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36379595 | Derived | Gaba F, Ash K, Blyuss O, Bizzarri N, Kamfwa P, Ramirez PT, Kotsopoulos IC, Chandrasekaran D, Gomes N, Butler J, Nobbenhuis M, Ind T, Heath O, Barton D, Jeyarajah A, Brockbank E, Lawrence A, Dilley J, Manchanda R, Phadnis S, Soar GO. Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative). Int J Gynecol Cancer. 2022 Dec 5;32(12):1606-1610. doi: 10.1136/ijgc-2022-004101. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| delayed cytoreductive surgery | Procedure | surgery after >5 cycles of chemotherapy |
|
| no surgery | Other | no cytoreductive surgery (>5 cycles of chemotherapy alone) |
|
| at time of surgery |
| D000291 |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |